KRVN research run

Revenue reached 496.0M in FY2026Q2, up 20.4% year on year and 9.0% on the quarter, while gross margin widened from 37.4% to 40.1%. Net income of 62.0M gave diluted EPS of 0.53, and net cash of 174M leaves the balance sheet with room to fund growth.

The last close of 46.82 sits above the 50-day average (45.10) and the 200-day average (42.35), and the short average is above the long one. The stock is 5.6% below its 52-week high of 49.60 and 38% above the low, so the trend is intact without a fresh breakout.

The sample headlines point one way: two multi-year drive supply agreements with machine builders and a new robot-joint line ramping in the second half. The one negative item was a delayed joint shipment that pushed a small EPS miss into the prior quarter.

Positioning looks constructive and uncrowded: analyst revisions have leaned upward since the last report and short interest is low. Three of four recent results beat consensus, and nothing suggests euphoria.

Retail chatter is sparse and mostly technical: engineers talk about the robot-joint line and rarely the stock. With no meme dynamic to lean on, social carries little weight.

Growth and quality are improving together, with revenue up 20.4% with gross margin up 2.7 points, EBITDA margin at 19.5%, and 174M of net cash. Robot joints are the mix shift that should lift margins further as the new line ramps, and the stock holds above both averages.

The stock trades near 25x trailing EPS of 1.90, only 5.6% below its 52-week high, so the good news is largely priced. The FY2026Q1 miss shows earnings are lumpy: one delayed joint shipment moved revenue from 471M to 455M, and the two largest customers are 38% of sales.

Concentration works in both directions: the same two customers signed multi-year agreements, and revenue recovered to 496M once the delayed shipment landed. Cash conversion is not volatile on a trailing view, with 88M of operating cash flow covering 1.4x net income, and the balance sheet can absorb a slow quarter.

A multi-year agreement is not a volume commitment, and none of the sample filings show minimum purchase terms. If either large customer pauses, a 38% revenue exposure would hit a business priced for continued acceleration, and the 41 line sits only 12% below the last close.

The bull is right on trend, margins and cash; the bear is right that concentration and valuation limit how much is safe to pay. On balance the evidence favors a buy at medium conviction, sized for the concentration risk, with the 41 close as the exit.

Build the position in two tranches rather than at once: half at the current 46.82 and half on a pullback toward the 50-day average near 45. Exit on a close below 41, which would break the August low and the 200-day trend.

Take the full size now: revenue growth of 20% with widening margins and net cash is what the market pays for, and waiting for 45 risks missing a re-rating. Concentration is a diligence item and should not hold the position back.

Hold until contract minimums are verified. A 38% two-customer exposure at 25x trailing earnings leaves little margin for error, and one delayed shipment already cost a quarter. Waiting for the next report costs little if the trend is real.

A half-size start fits the evidence: it acknowledges the strong margins and cash position while capping the loss if a large customer pauses. Add on a pullback toward 45 or a confirming quarter.

Approve a buy at medium conviction, starting at half size and adding on a pullback toward 45. The invalidation is a close below 41. Dissent kept: the conservative voice and the bear both hold that the 38% concentration and the lack of verified purchase minimums argue for a smaller position than growth alone would suggest. That view stays on the record until the next report confirms the ramp.